40
Participants
Start Date
November 21, 2019
Primary Completion Date
July 31, 2024
Study Completion Date
August 15, 2024
BDB001 (EIK1001)
BDB001 (EIK1001) is an immunotherapy agent.
Atezolizumab
Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.
Florida Cancer Specialists, Sarasota
Tennessee Oncology, Nashville
NEXT Oncology, San Antonio
South Texas Accelerated Research Therapeutics (START), San Antonio
Angeles Clinic, Los Angeles
Lead Sponsor
Seven and Eight
UNKNOWN
Eikon Therapeutics
INDUSTRY